|
|
|
|
 |
Why won't Mr Rudd trust the PBAC?
This week we again report on the extended delays to PBS listings of cancer drugs arising from the Cabinet approval process. The issue is an important one for many reasons but at bottom, while Finance Department bureaucrats comb through submissions already passed by the Pharmaceutical Benefits Advisory Committee, patients die |
|
|
|
|
| |
© 2007 Lush
Media | Privacy Statement | Subscribe
to Pharma in Focus |